BioNTech jab 97% effective against symptomatic cases
New study suggests Pfizer-BioNTech vaccine also prevents asymptomatic coronavirus infections
ANKARA
US pharmaceutical firm Pfizer and its German biotech partner BioNTech announced Thursday that the real-world data by the Israeli Health Ministry demonstrates their vaccine’s "high effectiveness," in preventing COVID-19.
The latest analysis by the Israeli Health Ministry using the public health data between Jan. 17 and March 6 showed that the Pfizer/BioNTech vaccine was at least 97% effective at preventing asymptomatic infections two weeks after the second vaccine dose.
The analysis also found that the vaccine’s effectiveness was 94% against asymptomatic coronavirus infections.
“These findings are also important, as the data were generated at a time when the SARS-CoV-2 variant B.1.1.7 (also known as UK variant of coronavirus) was the dominant strain,” co-founder and CEO of BioNTech Ugur Sahin said in a written statement.
Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
